Iloprost receives FDA approval for Treatment of Severe Frostbite

Iloprost, a synthetic prostacyclin analog used as vasodilator to treat pulmonary arterial hypertension (PAH), has been approved by the U.S. Food and Drug Administration for treatment of severe frostbite. This is first approved medication in the USA to treat severe frostbite in adults to reduce the risk of amputation.

Frostbite is a serious condition that require immediate medical attention. It is caused due to exposure to freezing temperature long enough to allow ice crystals to form in the tissues. People working outdoors in cold regions such as security personals, industrial workers, mountaineers or hikers etc are usually affected by frostbite. Amputation of fingers and toes because of frostbite is common in such regions despite advances in health care services.

Iloprost is a synthetic prostacyclin analog. It reverses vasoconstriction and inhibits platelet activation, acts as vasodilator, opens blood vessels and prevents blood clotting. It was first approved in 2004 for the treatment of pulmonary arterial hypertension (PAH).

Iloprost and thrombolytics are beneficial for treating frostbite. In Canada, patients with severe frostbite involving freezing of skin and underlying tissues and stoppage of blood flow have been successfully treated with iloprost. The old drug has now been approved by the U.S. Food and Drug Administration (FDA) for treatment of severe frostbite.

The FDA granted the approval to Eicos Sciences Inc. to manufacture iloprost for treatment of severe frostbite by the brandname “Aurlumyn”.

***

References:

  1. FDA Approves First Medication to Treat Severe Frostbite. Posted on 14 February 2024. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-treat-severe-frostbite/
  2. Regli, I.B., Oberhammer, R., Zafren, K. et al. Frostbite treatment: a systematic review with meta-analyses. Scand J Trauma Resusc Emerg Med 31, 96 (2023). https://doi.org/10.1186/s13049-023-01160-3
  3. Poole A. and Gauthier J. 2016. Treatment of severe frostbite with iloprost in northern Canada. CMAJ December 06, 2016 188 (17-18) 1255-1258; DOI: https://doi.org/10.1503/cmaj.151252
  4. Gruber, E., Oberhammer, R., Brugger, H. et al. Prolonged critical avalanche burial for nearly 23 h with severe hypothermia and severe frostbite with good recovery: a case report. Scand J Trauma Resusc Emerg Med 32, 11 (2024). https://doi.org/10.1186/s13049-024-01184-3

***

Latest

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both...

Future Circular Collider (FCC): CERN Council reviews Feasibility Study

The quest for the answers to the open questions (such as, which...

Chernobyl Fungi as Shield Against Cosmic Rays for Deep-Space Missions 

In 1986, the 4th unit of Chernobyl Nuclear Power Plant in Ukraine...

Myopia Control in Children: Essilor Stellest Eyeglass Lenses Authorised  

Myopia (or near-sightedness) in children is a highly prevalent...

Dark Matter in the Centre of our Home Galaxy 

Fermi telescope made clean observation of excess γ-ray emission...

Newsletter

Don't miss

COVID-19: Use of Hyperbaric Oxygen Therapy (HBOT) in Treatment of Severe Cases

COVID-19 pandemic has caused a major economic impact all...

Sukunaarchaeum mirabile: What Constitutes a Cellular Life?  

Researchers have discovered a novel archaeon in symbiotic relationship...

Fossils of Ancient Chromosomes with intact 3D Structure of Extinct Woolly Mammoth  

Fossils of ancient chromosomes with intact three-dimensional structure belonging...

Oxford/AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-2019) Found Effective and Approved

Interim data from the phase III clinical trial of...

Potential Use for New GABA-Targeting Drugs in Alcohol Use Disorder

Use of GABAB (GABA type B) agonist, ADX71441, in preclinical...

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced...
SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced by electric fields. Application of alternating electric fields (TTFields) to solid tumours selectively target and...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both strategic investment and active contribution in shaping its future direction.  Scientific European is an England-based media outlet providing multilingual...

Future Circular Collider (FCC): CERN Council reviews Feasibility Study

The quest for the answers to the open questions (such as, which fundamental particles make dark matter, why matter dominates the universe and why there is matter-antimatter asymmetry, what is force...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.